Non-Alcoholic Steatohepatitis (NASH) Market Analysis, Revenue Share, Company Profiles, Launches, & Forecast Till 2025Posted by sneha j on July 18th, 2022  Non-alcoholic steatohepatitis (NASH), is a common liver disease, often called as silent liver disease. It is asymptomatic until its later stages, and thus many patients are unaware of their condition. NASH is projected to lead the cause of liver transplantation in the U.S. in the coming years. Some major factors such as higher prevalence of NASH, expected launch of pipeline drugs, and higher number of unmet needs drive the growth of this market. However, poor diagnosis of NASH due to the lack of ideal diagnostic technologies limit the growth of the NASH market.
Download Sample Report : https://www.alliedmarketresearch.com/request-sample/224
At present, there is no FDA-approved drug available in the market for the treatment of NASH. Lifestyle interventions are the first-line approach to manage patients with NASH. Based on drug type, the market is segmented into vitamin E & pioglitazone, ocaliva, elafibranor, and selonsertib & cenicriviroc. Vitamin E & pioglitazone segment contributes majorly due to effectiveness in a treatment of steatosis, inflammation, hepatocyte ballooning, and scarring in NASH patients. Based on sales channel, the market is segmented into hospital pharmacy, online provider, and retail pharmacy. At present, the retail pharmacy segment is major revenue generator, and is estimated to show dominance during the forecast period due to the patient convenience and strong presence of retail pharmacies around the world. However, the online provider segment is projected to exhibit the fastest market growth due to rise in awareness of online pharmacies and increase in preference for online purchase of drugs over the traditional methods.
Get Detail Report : https://www.alliedmarketresearch.com/non-alcoholic-steatohepatitis-nash-market Like it? Share it! More by this author |